| Objective: To observe the effects of jianpi yishen huoxue decoction combine with dapagliflozin on inflammatory factors, oxidative stress and serum neutrophil gelatinase associated lipocalin (NGAL), advanced glycation end products (AGEs) and monocyte chemoattractant protein 1 (MCP-1) in patients with diabetic nephropathy (DN). Methods: According to the random number table method, 120 DN patients who were admitted to our hospital from June 2021 to March 2023 were divided into control group (60 cases, treated with dapagliflozin on the basis of routine treatment ) and study group (60 cases, treated with jianpi yishen huoxue decoction on the basis of control group). The efficacy, inflammatory factors [interleukin-1β (IL-1β), tumor necrosis factor-α (TNF-α), C reactive protein (CRP)], renal function [serum creatinine (Scr), blood urea nitrogen (BUN), Urinary microalbumin/creatinine ratio (UACR)], oxidative stress [malondialdehyde (MDA), superoxide dismutase (SOD)] and serum AGEs, NGAL, MCP-1 levels were compared between two groups, and the occurrence of adverse reactions during treatment was observed. Results: The total clinical effective rate in study group was higher than that in control group (P<0.05). Scr、BUN and UACRdecreased in two groups 2 courses after treatment, and study group were lower than those of control group (P<0.05). CRP, TNF-α and IL-1β in two groups decreased 2 courses after treatment, and study group were lower than those of control group (P<0.05). MDA decreased in two groups 2 courses after treatment, and study group was lower than that of control group. SOD increased, and study group was higher than that of control group (P<0.05). NGAL, AGEs and MCP-1 decreased in two groups 2 courses after treatment, and study group were lower than those of control group (P<0.05). There was no difference in the incidence of adverse reactions between two groups (P>0.05). Conclusion: Jianpi yishen huoxue decoction combine with dapagliflozin can effectively reduce oxidative stress and inflammatory response in DN patients, and regulate the levels of serum AGEs, NGAL and MCP-1. |
